The future has arrived #CUBETechFair

CUBE10 - 12 May 2017, Berlin, Germany.
Startups are setting up, speakers are tweaking their talks, and CUBE Tech Fair is ready for you... The inaugural CUBE Tech Fair kicks off tomorrow, and what a show they have for you. CUBE Tech Fair has brought the Crème de la Crème of the tech world to Berlin.

Over 300 startups from our ecosystem will be exhibiting, in addition to pitching for a €1 million prize in CUBE Challenge. The final round will be judged by Apple Co-Founder, Steve Wozniak.

Let's welcome keynote speeches by:

  • Pablos Holman (Founder of Intellectual Ventures Laboratory, notorious hacker)
  • Michael Müller (Mayor of Berlin)
  • Steve Wozniak (Co-Founder of Apple),
  • Robin Wright (Award-winning actress, tech activist),
  • Brigitte Zypries (Federal Minister of Economic Affairs and Energy)

The fireside chats, keynotes speeches, and panel discussions will deep-dive into specific industry areas. Topics include:

  • Infrastructure & Interconnectivity
  • Digital Health & Life Sciences
  • Machinery & Manufacturing
  • Cybersecurity & Hacking
  • Climate Change & Smart Energy Systems
  • Blockchain Innovations and more!

The Welcome Reception has filled up fast, and organisers already have exceptional guests including top startups, corporates and investors - and for good reason. Come, network and enjoy food tech at it's best - CUBE will be serving up bites from the incredible German Michelin-starred chef Christian Lohse. And on top of that all the ingredients are being provided by anti-food-waste startup SirPlus.

Don't have a booked seat? No problem! The event is still open to all Tech Fair badge holders!

On Thursday night, organisers take to the CityCube's terrace for the official Tech Fair party - they will of course be bringing Berlin's party spirit to the tech world.

Still don't have a ticket?! Get one now!

World Pharma News readers can benefit from an exclusive discount - get 30% off the ticket price using our unique promo code worldpharmanewsCUBE17 when you register online here.

About CUBE
CUBE is a Berlin-based global innovation ecosystem that aims to promote, create and foster partnerships between industry players and startups in life sciences & digital health, machinery & manufacturing as well as infrastructure & connectivity. Being part of the CUBE ecosystem allows all participants to collaborate on innovative products and ideas in response to concrete industry needs.

The annual CUBE Tech Fair, our flagship event, will take place for the first time in May 2017. For further information, please visit http://tech-fair.cube-global.com.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche purchases shares in tender offer for Ignyta…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares v...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]